Abstract
Background: COVID-19 is an infectious disease caused by a newly identified strain of coronavirus (SARS-CoV-2). This strain is responsible for respiratory infections in humans.
 Objective: The objective of this study was to analyze the clinical efficacy and safety of convalescent plasma (CP) therapy in coronavirus disease 2019 (COVID-19) cases.
 Methodology: This was an experimental trial of COVID-19 patients treated with convalescent plasma (CP) therapy, these patients were admitted in Lahore General Hospital, Lahore, Pakistan during April 24 to august 24, 2021.
 Results: Pearson correlation was applied to extract the efficacy of convalescent plasma therapy (CP). A p-value ≤0.05 was considered significant. 16 out of 20 patients (80%) were completely recovered from COVID-19.
 Conclusion: Convalescent plasma (CP) proved to be an effective and safe therapy for confirmed cases of COVID-19. However, two critically ill patients died.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
